Peer-reviewed veterinary case report
Comparing two dog itch medicines ilunocitinib and oclacitinib
By Forster, Sophie et al.·Published in Veterinary dermatology·2025·Elanco Animal Health Ltd, United Kingdom·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Comparative efficacy and safety of ilunocitinib and oclacitinib for the control of pruritus and associated skin lesions in dogs with atopic dermatitis.
- Species:
- dog
Plain-English summary
A group of 338 dogs with atopic dermatitis (a skin allergy causing itching and lesions) were treated with either ilunocitinib or oclacitinib to see which worked better. Both medications initially reduced itching and skin problems, but ilunocitinib showed better results after a month, with more dogs experiencing relief from itching and skin lesions. Owners reported that dogs on ilunocitinib had a significantly better response overall compared to those on oclacitinib. Both treatments were safe for the dogs throughout the study.
People also search for: dog itching treatment · atopic dermatitis medication for dogs · ilunocitinib vs oclacitinib for dogs
Abstract
BACKGROUND: Janus kinase inhibitors (JAKi) have been shown to reduce pruritus and improve associated inflammatory skin lesions in canine atopic dermatitis (cAD). OBJECTIVE: To evaluate the efficacy and safety of ilunocitinib, in comparison to oclacitinib, for the control of cAD in a randomised, blinded trial. ANIMALS: Three-hundred-and-thirty-eight dogs with cAD. MATERIALS AND METHODS: Dogs were randomised to receive oclacitinib (0.4-0.6 mg/kg twice daily for 14 days; then once daily) or ilunocitinib (0.6-0.8 mg/kg once daily), for up to 112 days. Owners assessed pruritus using an enhanced Visual Analog Scale (PVAS). Investigators assessed skin lesions using the Canine Atopic Dermatitis Extent and Severity Index, 4th interaction (CADESI-04). RESULTS: Reduction in pruritus and CADESI-04 scores was similar for both treatment groups from Day (D)0-D14. PVAS scores increased between D14 and D28 for oclacitinib and decreased for ilunocitinib. On D28 to D112, mean PVAS and CADESI-04 scores were significantly lower for ilunocitinib compared to oclacitinib (p ≤ 0.003 and p ≤ 0.023, respectively). On D28 to D112, a greater number of ilunocitinib-treated dogs achieved clinical remission of pruritus (i.e. PVAS score <2). Subjective assessment of overall response was significantly better for ilunocitinib on D28 to D112 (p ≤ 0.002). Both drugs demonstrated similar safety throughout the study. CONCLUSIONS AND CLINICAL RELEVANCE: Ilunocitinib rapidly and safely controlled signs of cAD. Ilunocitinib demonstrated significantly better control of pruritus and skin lesions compared to oclacitinib, with more dogs achieving clinical remission of pruritus.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/39757965/